CRISPR Therapeutics AG

CRSP

Add to Watchlist

54.830USD

+2.410+4.60%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

CRISPR Therapeutics AG's Score

Industry at a Glance

Industry Ranking

87 / 384

Overall Ranking

216 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

CRISPR Therapeutics AG Highlights

StrengthsRisks

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.51M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.51M.

Overvalued

The company’s latest PE is -8.89, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.20M shares, decreasing 12.26% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.54K shares of this stock.

Analyst Rating

Based on 27 analysts

Buy

Current Rating

80.309

Target Price

+46.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of CRISPR Therapeutics AG is 5.78, ranking 315 out of 384 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.46M, representing a year-over-year increase of 68.55%, while its net profit experienced a year-over-year increase of 9.61%.

Score

Industry at a Glance

Previous score

5.78

Change

0



Financials

7.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.67

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of CRISPR Therapeutics AG is 6.72, ranking 223 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.89, which is -100.00% below the recent high of 0.00 and -416.78% above the recent low of -45.96.

Score

Industry at a Glance

Previous score

6.72

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 87/384

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of CRISPR Therapeutics AG is 7.59, ranking 288 out of 384 in the Biotechnology & Medical Research industry. The average price target is 74.50, with a high of 268.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.59

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of CRISPR Therapeutics AG is 7.40, ranking 100 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 59.89 and the support level at 49.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.07

Change

0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of CRISPR Therapeutics AG is 7.00, ranking 79 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 73.84%, representing a quarter-over-quarter decrease of 13.03%. The largest institutional shareholder is Catherine Wood, holding a total of 11.31M shares, representing 11.73% of shares outstanding, with 0.34% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

10.52M

+7.51%

BlackRock Institutional Trust Company, N.A.

6.67M

+6.79%

Orbis Investment Management Ltd.

5.95M

+19.43%

State Street Investment Management (US)

3.75M

-6.33%

T. Rowe Price Investment Management, Inc.

3.23M

-1.71%

GSK plc

3.22M

--

Geode Capital Management, L.L.C.

2.25M

+5.05%

George (Simeon J.)

1.05M

--

SR One Capital Management, LP

2.04M

--

Fidelity Management & Research Company LLC

1.95M

+3.62%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CRISPR Therapeutics AG is 5.14, ranking 52 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

CRISPR Therapeutics AG

CRSP

6.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment